Skip to Main Content

South Carolina life Sciences

  • sam patrick posted an article
    Development is the largest agriculture-based Opportunity Zone project in the nation see more

    Compliments of Post and Courier

    Environmental permitting is underway for the Agriculture-Technology Campus in Hampton County, with a goal of starting operations at the indoor farming supersite by the end of next year.

    The $314 million development is being billed as the largest agriculture-based Opportunity Zone project in the nation. Its announcement last September at the Southern Carolina Industrial Campus off Interstate 95 in Early Branch attracted hundreds of boosters, including the nation’s top farm official at the time in Sonny Perdue — the agriculture chief under former President Donald Trump.

    Thing have been relatively quiet since then, but plenty of work has been taking place behind the scenes, said Kay Maxwell, marketing manager for the Southern Carolina Regional Development Alliance.

    She said a group of precision farming specialists from the Netherlands spent months conducting studies at the industrial park to determine how greenhouses there can get the maximum benefit from sunlight, humidity and other weather conditions. The Netherlands is the world’s second-leading agricultural exporter, behind the United States, and has pioneered indoor growing techniques that use little water or soil and no pesticides.

    More traditional studies — such as wetlands permitting and geotechnical engineering — are now taking place, Maxwell said. The alliance also is marketing the project to companies interested in either growing crops at the property or using an onsite packaging and distribution center to deliver South Carolina-grown products to store shelves.

    “We have talked to companies as far as Europe and Asia, as well as a lot of domestic companies, that are very interested in South Carolina because of this project,” Maxwell said. “There are a lot of different avenues in which other companies can be involved.”

    While the Ag-Tech Campus has five years to qualify for state and local tax credits, Maxwell said she expects some operations will begin much sooner.

    The project also qualifies for a $7 million rural infrastructure grant from the state that would pass through Hampton County Council, though none of the funds have been released to date, according to the S.C. Commerce Department.

    The Ag-Tech Campus is a partnership between Columbia-based finance group GEM Opportunity Fund and a trio of food and packaging firms that will grow produce in environmentally controlled greenhouses at the 1,000-acre site.

    Zeb Portanova, chief executive of GEM, said in a March 30 interview with Fundviews Podcast that he had recently submitted a financing package for the project with the U.S. Department of Agriculture.

    The agency is providing grants for Opportunity Zone projects, which are also eligible for federal tax breaks and fall under a program designed to encourage investment in low-income urban and rural communities.

    Portanova has said the Ag-Tech Campus will create roughly 1,500 jobs by 2025. Another GEM project — a $30 million hemp growing and processing facility — will be nearby. Maxwell said greenhouses are already being constructed for the latter project, which is expected to create 107 jobs, and start operations by the end of this year.

  • sam patrick posted an article
    Ten years in a row for life sciences firm Rhythmlink see more

    For the tenth consecutive year Rhythmlink has been awarded a spot on the “Best Places to Work in South Carolina” list in the Small Employer category, honored by the South Carolina Chamber of Commerce. This year Rhythmlink placed 13 out 20 total companies in this category, earning a spot on a final list of the 81 most innovative and top-notch employers across the state.

    “Rhythmlink takes pride in achieving this honor for the tenth consecutive year,” said Shawn Regan, Co-founder and Chief Executive Officer for Rhythmlink International, LLC. “We could not achieve our mission of improving patient care or uphold our values and culture without the significant contribution of our employees, and this honor helps us know we remain on the right track for making that possible,” said Regan.

    Companies from across the state entered the two-part survey process to determine the Best Places to Work in South Carolina. The first part consisted of evaluating each company’s workplace policies, practices, philosophy, systems and demographics. The second part consisted of an employee survey to measure the employee experience. The combined scores determined the top companies and the final ranking. Several questions on the survey dealt with how Rhythmlink has responded to challenges of the COVID-19 pandemic, and how it has affected the workplace.

    Joe Straczek, Chief Financial Officer for Rhythmlink, believes that despite the challenges, Rhythmlink employees remained focused and dedicated to their work. “As a health care company, our employees know the value of their work in our industry, and believe they have an opportunity to make a difference,” said Straczek. “One of the things that makes our culture special is a willingness and ability to adapt to changes and struggles, while always keeping the customer top of mind.”

    Ranked companies were recognized at an annual reception and awards dinner at the Columbia Convention Center on August 4, 2021.

     

    About Rhythmlink

    Rhythmlink International is a medical device manufacturer specializing in devices that help connect patients to machines to record or elicit physiologic information. Rhythmlink designs, manufactures, and distributes a variety of medical devices for intraoperative neuromonitoring, electroencephalography, evoked potentials, polysomnography, long-term epilepsy monitoring and critical care units. Founded by neurodiagnostic technologists and engineers in 2002, Rhythmlink enhances patient care worldwide by transforming medical device technology that links patients to equipment. Rhythmlink also offers custom packaging, custom products, private labeling, and contract manufacturing services.

  • sam patrick posted an article
    Once again, Lou Kennedy and Nephron step up for South Carolina see more

    Courtesy of the Associated Press

    A South Carolina-based pharmaceutical manufacturer that has offered coronavirus vaccines to the public and run thousands of COVID-19 tests throughout the pandemic will now require all of its employees to get inoculated.

    Nephron Pharmaceuticals Corp. is mandating that all of the company’s nearly 2,000 workers be fully vaccinated or have started a two-dose vaccine series by Aug. 27, unless the employee has “an exemption or reasonable accommodation,” according to CEO Lou Kennedy.

    The company is one of the first major businesses in South Carolina, other than hospitals, to publicly declare such a directive. Details of the requirement were shared with The Associated Press ahead of an official announcement Monday.

    “As COVID-19 cases, driven by the deadly serious Delta variant, continue to impact communities and businesses alike, we can be one of the first businesses of our size to have a fully-vaccinated workforce,” Kennedy wrote in a company-wide letter.

    Kennedy told reporters that employees who are not vaccinated by the deadline and can’t provide a medical or religious exemption will be fired, and she isn’t worried about lawsuits.

    “I’ll be very sad if we lose even the first person,” Kennedy said. “I hate that, but we’ve got to do what is right, to keep us healthy so we can keep others healthy.”

    Nephron, which makes a number of drugs used to treat COVID-19 patients, is also mandating all visitors, vendors and guests be fully vaccinated. Those who need the shots can get them from Nephron itself, which has run a vaccine site in West Columbia since February.

    The company is still compiling data on how many of its workers are vaccinated.

    A growing number of hospitals around the state, including the Medical University of South Carolina and Tidelands, have made vaccination a requirement for health care employees. Prisma Health, South Carolina’s largest hospital system, has offered incentives to staffers instead, news outlets have reported.

    The Nephron announcement comes as vaccine rates continue to lag. Less than half of eligible South Carolinians were fully vaccinated as of last week, according to data from the South Carolina Department of Health and Environmental Control.

    Although most businesses in the state have yet to implement such requirements, the resurgence of the virus with the highly contagious delta variant has prompted many to consider a mandate, S.C. Chamber of Commerce President and CEO Bob Morgan told The Associated Press on Monday.

    More and more businesses will likely require employees to be vaccinated, following Nephron’s lead and the expected full approval of the vaccine by the Food and Drug Administration later this fall, Morgan said: “Momentum is growing.”

    Lawmakers in the South Carolina Senate did approve a proposal that would prevent employers from requiring COVID-19 vaccines for workers earlier this year. That measure still awaits House action.

  • sam patrick posted an article
    Lou Kennedy authors a perspective every South Carolina resident should read see more

    Compliments of Post and Courier

    Nephron Pharmaceuticals Corp. manufactures lifesaving medications that help people breathe. In the midst of a pandemic, it is more critical than ever that our team stays healthy, so we can keep patients healthy.

    This was one reason we stayed motivated over the past year to step up for our community, state and nation to aid the response to COVID-19. When the opportunity arose for Nephron to partner with Dominion Energy South Carolina and launch a COVID-19 vaccination drive-thru, we embraced it — just as many of our employees, myself included, jumped at the chance to be vaccinated.

    It was the least we could do to help keep South Carolina’s recovery on track. After all, we have been proud of the way our state, guided by Gov. Henry McMaster, has led. We struck the right balance between public health and economic prosperity. We never closed down, and we avoided many of the problems neighboring states have battled.

    However, I would be remiss if I failed to mention the lag our state — and, frankly, our company — has seen in citizens being vaccinated. The initial enthusiasm for getting vaccinated has given way to hesitancy. I want to change that. I hope my colleagues around the business community will join me in the effort.

    Why is it important to me for the people of South Carolina, the employees of our company and workers everywhere to get vaccinated? 

    After a year of masks and mandates, viruses and virtual meetings, I am tired of having the economy impacted, and recreation curtailed, by concerns that interacting with people could lead to long-term health challenges, such as those associated with COVID-19. I agree with our governor: We do not need new restrictions in South Carolina. It is time to return to normal — for good.

    I also believe in science. As the CEO of one of the fastest-growing pharmaceuticals manufacturers in the country, I work with dozens of brilliant scientists. We know there are real concerns about contracting COVID-19 and the new, dangerous strains of the virus cropping up around the world.

    If we truly want to return to normal, and do so in a permanent way, then there is no alternative to getting vaccinated. Luckily, in South Carolina, there are countless places where vaccines are available. Come to the Nephron drive-thru vaccination location (in West Columbia) and get your shot. There is no charge. Or contact the state Department of Health and Environmental Control about where to get vaccinated. Again, there is no charge.

    Do you own a business? Give your employees incentives to get the shot. We did. Employees who received the vaccine by a certain date at Nephron were entered into a drawing to receive free paid time off. This was a win-win — for workers, it was a chance to earn a meaningful prize, and for the company, it meant a safer and healthier work environment.

    Nephron employees who still have not been vaccinated are required to wear masks. Like other critical health care and manufacturing facilities, Nephron is a place too many people depend on for us to risk a widespread outbreak of any virus. What we hope is that we can encourage enough of our employees to get vaccinated that we do not have to consider additional mandates or more serious measures in response to unvaccinated employees.

    Vaccinations remain one of the surest ways each of us can do the right thing — by our friends, families, state and nation — during these unprecedented days. If you have not been vaccinated, I hope you will join me and get the shot. Each of us can contribute to the health and safety of our companies and our country. Doing so may mean the difference between keeping the place where you work open and seeing it closed — not to mention the difference between life and death.

    Lou Kennedy is CEO of Nephron Pharmaceuticals Corporation and a Lexington resident.

  • sam patrick posted an article
    Expanded use of test builds on previous month’s publication of successful interim clinical data see more

    Functional precision oncology innovator Kiyatec announced today that it is initiating use of the 3D Predict™ Glioma test outside of its 3D-PREDICT clinical study. Recently published peer-reviewed data demonstrated successful use of this test for patients with either newly diagnosed or recurrent high-grade gliomas, which includes glioblastoma (GBM).

    In choosing July 21, 2021, to announce the expanded use of its test, KIYATEC joins the country in shining a light on glioblastoma, which is the most common, treatment-resistant, and deadliest type of brain cancer. A recent bipartisan U.S. Senate resolution declared today as Glioblastoma Awareness Day in order to highlight the severity of GBM, and show support for individuals who are currently living with GBM, as well as caregivers and families. Additionally, the resolution encourages continued investment into glioblastoma research and treatments.

    “At the core of KIYATEC’s mission is the desire to improve cancer patients’ lives. We’re excited to take the next step in fulfilling this mission by expanding the use of our testing for patients with GBM, which is such an aggressive cancer with few treatment options,” said Lillia Holmes, Chief Operations Officer at KIYATEC.

    In a patient, the biological interaction between their live cancer cells and the administered therapy drives treatment outcomes. Measurement of this interaction, before prescribing a treatment plan, is not typically part of today’s cancer treatment paradigm. KIYATEC’s test results add this measurement into the information that informs oncologists’ treatment decisions for a given patient. This approach translated to patient benefit while demonstrating clinically relevant accuracy, as documented in the June Neuro-Oncology Advances publication.

    The 3D Predict™ Glioma test is designed to work within the current framework of standard of care for high-grade glioma patients. Since live cells are required for the test, a patient’s oncologist must sync sample submission with the timing of the first surgery for newly diagnosed patients, or recurrent surgeries for relapsed patients. Oncologists interested in the potential use of the test to inform their decision-making, or requesting test kits to provide samples, should contact the company at medical.affairs@kiyatec.com.

    “Our goal is to provide oncologists with a more effective decision-making tool, by combining individual patient’s cancer cells with potential treatment drugs,” said Stephen Shuford, first author on the company’s recent Neuro-Oncology Advances publication.

    The Senate resolution recognizes that:

    • The five-year survival rate for GBM patients is 7%,
    • The median length of survival is 8 months,
    • Approximately 13,000 Americans will be diagnosed with GBM in 2021,
    • Brain cancer has the highest per-patient initial cost of care, and
    • Despite being first described over a century ago, there are only four FDA approved drugs and one device for GBM.

    KIYATEC aims to make a meaningful impact for patients who are facing this challenging cancer.

    About KIYATEC

    KIYATEC is a functional precision oncology company that measures the response of each patient’s live cancer cells to inform oncologists’ treatment selection decisions. The company’s Clinical Services business offers or is developing clinical tests for high-grade glioma, ovarian, breast, and non-small cell lung cancers, and rare tumors in its CLIA-certified lab. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

  • sam patrick posted an article
    GHGC earns major grant see more

    The National MPS Society has awarded a $100,000 grant to Heather Flanagan-Steet, PhD, Director of Functional Studies at the Greenwood Genetic Center (GGC). Flanagan-Steet will lead the two-year project designed to better understand the biology of skeletal disorders in patients with these rare disorders and identify new therapies.

    Mucopolysaccharidoses (MPS), as a group, affect approximately 1 in 25,000 individuals. These progressive diseases cause widespread damage throughout the body, including the heart, bones, joints, respiratory system and central nervous system, leading to a shortened lifespan. Skeletal abnormalities are a common feature of MPS disorders and can lead to pain, impaired growth, and limited mobility.

    Flanagan-Steet’s work will involve the use of zebrafish models of three MPS disorders, MPS II (Hunter syndrome), MPS IVA (Morquio syndrome), and ML II (I-cell disease), to pinpoint common pathways involved in the bone and cartilage disease seen in patients with MPS.

    “Because zebrafish and humans share 70% of the same DNA, we can mimic MPS in the zebrafish, allowing us to study how the patient mutations actually cause the clinical features of these disorders,” said Flanagan-Steet. “The fish provide a really powerful tool both to help us understand exactly how these skeletal issues develop and then to assess which treatments may improve or prevent those issues. By directly comparing the mechanisms in these three different disease models, we hope to identify therapeutic approaches that may benefit multiple diseases.”

    The MPS Society provides support resources for families as well as funding for research into this group of disorders which can affect the health, development, quality of life, and lifespan of affected individuals. GGC has a long-standing interest in MPS disorders including providing clinical care, diagnostic testing, and research for many of these rare conditions.

    “We are so grateful for the support of the MPS Society, an organization led by families who are dedicated to raising awareness, supporting research, and ultimately finding cures for these disorders,” said Flanagan-Steet. “We are excited to advance this work and contribute to improving the quality of life for all individuals and families impacted by MPS disorders.”


    About the MPS Society

    The National MPS Society exists to cure, support, and advocate for MPS and ML. Their mission serves individuals, families, and friends affected by Mucopolysaccharidoses and Mucolipidosis through supporting research, supporting families, and increasing public and professional awareness. For more information on MPS and ML, please visit www.mpssociety.org.

  • sam patrick posted an article
    MUSC completes purchase of hospitals see more

    Compliments of Post and Courier

    Providence Health is no more in the Capital City.

    The hospital, originally founded by the Catholic Sister of Charity, is now state-owned MUSC Health Columbia Medical Center, following the finalization of its purchase by MUSC Health University Medical Center.

    With the $75 million purchase South Carolina’s second-largest hospital system added Providence’s downtown and northeast facilities to its fleet of care centers around the state, as well as the former KershawHealth hospital in Camden — now known as MUSC Health Kershaw Medical Center — and the emergency room in Fairfield County — now known as MUSC Health Fairfield Emergency and Imaging.

    The hospitals were previously owned by Tennessee-based for-profit LifePoint Health.

    All of LifePoint’s existing 2,000 employees were offered to remain on staff under the new ownership, said MUSC Health CEO Dr. Pat Cawley said.

    The deal takes MUSC to more than 2,000 beds and 19,000 employees across the state.

    Buying Providence Health is the latest in MUSC’s major expansion outside of its Charleston base where it had been contained for nearly 200 years before it branched outside the area for the first time with the acquisition of four community hospitals in 2019. The public, nonprofit health system receives financial support out of the state budget.

    The deal comes months after Prisma Health, the state’s largest health care system terminated its own agreement to purchase LifePoint’s facilities. Prisma, which operates three major hospitals in Columbia, abandoned its efforts April 9 after it was plagued for more than a year by legal and regulatory challenges.

    Had the purchase been finalized, it would have taken the Columbia area down to two hospital systems — Prisma and Lexington Medical Center. And it would have made the state’s largest system even larger.

  • sam patrick posted an article
    USC earns award of excellence see more

    In recognition of their dedication and innovations in overcoming the challenges of delivering the experiential curriculum during the past year, the American Association of Colleges of Pharmacy Experiential Education Section has bestowed the Award for Excellence in Experiential Education upon the faculty and staff of experiential offices at the colleges and schools of pharmacy, including the University of South Carolina College of Pharmacy.

    The Experiential Education team of Jennifer Baker, director of experiential programs; Whitney Maxwell, associate director of experiential programs; Kathryn Kenard, student service program coordinator; and Nancy Blaisdell, administrative assistant, received certificates of recognition from the AACP during a presentation by Julie Sease, interim dean of the College of Pharmacy.

    The AACP Experiential Education Section Award of Excellence in Experiential Education is normally presented each year to an individual, but this year, the organization chose to recognize programs across the country.

    When the University closed in March 2020, the Office of Experiential Education for the College of Pharmacy mobilized to a virtual unit overnight as there could be no pause in operations to keep students progressing through the Pharm.D. curriculum. With the status of hundreds of rotations changing on what seemed like an hourly basis during the spring and summer of 2020, Baker and Maxwell navigated rotation rescheduling while Kenard and Blaisdell tirelessly worked through site onboarding requirements to efficiently move students on and off rotation without missing a beat.

    “Through the hard work and commitment of our preceptors and practice sites, we were able to successfully graduate the Classes of 2020 and 2021 on time,” says Baker. “Our team was dedicated to our students even while serving on the front lines of the battle against COVID-19. While our experiences were not unique, as everyone’s worlds were turned upside down during the pandemic, I can confidently say that our students and College are blessed with the best preceptors and faculty.

    “We are so grateful for the unwavering support from College administration and for this recognition by the AACP Experiential Education Section. It was incredible to see the collaboration that occurred within our profession at the local, state and national level to support all pharmacy students.”

  • sam patrick posted an article
    7 years in a row for MUSC see more

    MUSC Health University Medical Center in Charleston was named by U.S. News & World Report for the seventh year in a row as the No. 1 hospital in South Carolina, with three of MUSC Health’s specialty areas ranking among the best in the entire country: ear, nose and throat; gynecology and cancer.

    Seventeen other MUSC Health programs are considered “high performing” specialties, procedures or conditions in the 2021-2022 U.S. News & World Report rankings: gastroenterology and GI surgery, abdominal aortic aneurysm repair, aortic valve surgery, heart attack, heart bypass surgery, heart failure, back surgery (spinal fusion), hip replacement, kidney failure, chronic obstructive pulmonary disease (COPD), lung cancer surgery, pneumonia, stroke, colon cancer surgery,  rheumatology, orthopedics and urology.

    In addition, MUSC Health Florence Medical Center is designated as “high performing” in chronic obstructive pulmonary disease (COPD), heart failure, heart attack and kidney failure.

    “Once again, South Carolinians can take great pride and comfort in the knowledge that their only public, statewide hospital system is consistently cited as one of the best in the country,” said Patrick J. Cawley, M.D., MUSC Health CEO and MUSC vice president for Health Affairs, University. “It’s a transformational time in health care and these rankings are a testament to our care team’s commitment to ensure that our patients are receiving the right care, in the right place and at the right time. The achievements in our Charleston and Florence divisions made despite the pandemic should remind us all what’s possible through innovation, teamwork, and growth.”

    U.S. News & World Report unveiled the 32th edition of the Best Hospitals rankings at https://health.usnews.com/best-hospitals/rankings. Designed to help patients with life-threatening or rare conditions identify hospitals that excel in treating the most difficult cases, Best Hospitals 2021-22 includes consumer-friendly data and information on 4,750 medical centers nationwide in 15 specialties and 17 procedures and conditions. In the 15 specialty areas, 175 hospitals were ranked in at least one specialty. In rankings by state and metro area, U.S. News & World Report recognized hospitals as high performing across multiple areas of care.

    “I am so proud that U.S. News & World Report has recognized MUSC Health Florence Medical Center as high performing in four areas  – chronic obstructive pulmonary disease (COPD), heart failure, heart attack and kidney failure,” said Jay Hinesley, MUSC Health Florence Division CEO. “The last year has been a challenge for everyone in health care, and these recognitions are a true testament to all the hard work of our care team members and their dedication to our patients, families and communities. We are committed to continuing to preserve and optimize human life in South Carolina and beyond.”

    The U.S. News & World Report Best Hospitals methodologies, in most areas of care, are based largely or entirely on objective measures such as risk-adjusted survival and readmission rates, volume, patient experience, patient safety and quality of nursing, among other care-related indicators.

    1. - U.S. News & World Report’s produced Best Hospitals with RTI International, a leading research organization based in Research Triangle Park, N.C.

  • sam patrick posted an article
    Life sciences booming in Spartanburg, Upstate see more

    Spartanburg County – and the entire Upstate – are welcoming a growing interest and investments from life sciences companies. The Upstate has a long-established history and infrastructure that have supported life sciences companies with raw materials, production and packaging operations, and distribution.

    Now, new research and innovation businesses are further supporting industry growth and fueling an ecosystem ripe for start-ups.

    More than 670 life sciences firms of all sizes call the Upstate home, with 13 companies announcing new locations in the area in the last few years.

    The newest of those companies in Spartanburg is Epica International, the leader in advanced, ultra-high-resolution mobile medical imaging and robotic applications for human and animal health, and industrial enterprises.

    The company announced its headquarters and operations in Spartanburg, covering its subsidiary companies Epica Human Health, Epica Animal Health and Roboticom. Epica established corporate, imaging and robotic system demos at its facility, currently located inside the Spark Center SC on the Tyger River Campus of Spartanburg Community College.

    “Epica’s investment in Spartanburg goes hand-in-hand with a diversified economic development strategy we’ve put in place countywide, targeting specifically investments from bioscience and life sciences industries,” said OneSpartanburg, Inc. Chief Economic Development Officer Katherine O’Neill. “These types of advanced, heavy-technology industries coming to our county gives us a considerable strategic advantage for future development and job growth.”

    Another life sciences company – Pall Corporation – announced its intent to invest in Spartanburg County earlier in 2021. Pall announced its Spartanburg County operations would create 425 new jobs and $30.2 million in investment.

    Pall serves the needs of customers across the broad spectrum of life sciences and industry and works with clients around the world to advance health, safety and environmentally responsible technologies. The company’s Spartanburg facility supports the rapid development of vaccines and therapeutics, including COVID-19 vaccines.

    "Spartanburg County provides Pall with the diverse workforce we need to manufacture life-saving therapeutics and vaccines. We look forward to building our presence in this county,” said Pall Life Sciences President Joseph Repp at the time of the company’s announcement.

    Statewide, South Carolina has a significant presence in the medical device sector. And the manufacturing supply chain is robust when it comes to life sciences, mirroring the strength of the area’s overall manufacturing prowess.

    From 2015-2019, medical devices and equipment companies added 35% more jobs and accounted for 11.5% of the new companies coming to the Upstate. And on top of that, more than 700 clinical trials are being undertaken across the Upstate at any given time in the fields of oncology, companion diagnostics, genetics and more.

    The Upstate in particular has a network of acclaimed hospitals, technical training schools and more than 26 colleges and universities actively working with industry leaders and educators on all levels to ensure access a highly-skilled workforce for decades to come.

    “Spartanburg’s historic advantages when it comes to infrastructure, distribution capabilities and even the county’s location, make it a favorable home for continued investments from biosciences and life science industries,” said O’Neill. “That positions us well for the future as these industries continue to bring higher-wage, knowledge-based jobs to Spartanburg.”

  • sam patrick posted an article
    Issues over $3 million in funds to colleges, universities see more

    SCRA has announced the funding of over $3.3 million to selected colleges and universities for translational research projects to address key challenges facing the state’s industrial base. SCRA’s funding is being matched by the academic institutions and industry partners, bringing the total amount of the projects to over $6.7 million.

    The projects are being funded through the SCRA-Academia Collaboration Team (SACT) program. The goal of the SACT is to connect industry with multi-institutional academic teams and build bridges among the institutions to foster engagement and advance technologies, many of which will enter the marketplace and lead to the creation of South Carolina-based jobs.

    • $1.8 million was awarded to Clemson University to modernize South Carolina’s manufacturing assets to enable Industry 4.0 (the ongoing automation of traditional manufacturing and industrial practices, using modern smart technology). Clemson is partnering with the University of South Carolina, the Medical University of South Carolina, South Carolina State University, Greenville Technical College, and Trident Technical College.
    • $1.2 million was awarded to the University of South Carolina to enable factory-to-factory networking for the future of manufacturing operations. The University is partnering with Clemson University, Greenville Technical College, and Midlands Technical College.
    • $305,000 was awarded to Francis Marion University to improve workforce readiness and capabilities in South Carolina. The University is partnering with The Citadel.

    “I’m energized by the opportunities and positive outcomes from this intersection of academic research, entrepreneurship, and industry in the state. These collaborations provide the greatest potential for innovation, economic growth, and overall advancement of the region,” said Kella Player, SCRA Program Manager.

    SCRA’s program directors and industry advisors will review the progress on these SACT research projects on an ongoing basis. Funds will be provided in stages as milestones are met.

    “We are fortunate to have high-quality research and development being conducted at our state’s colleges and universities. Many of the technologies on which they are working today will produce the new companies of tomorrow. It’s a honor for SCRA to support these collaborations,” said Bob Quinn, SCRA Executive Director.

    Since 2018, SACT grants have funded 17 collaborations among South Carolina-based academic institutions and 41 industry partners. These projects have produced an 8:1 multiple in additional funding from other sources such as industry and the federal government.

    SCRA grants are funded in part by the Industry Partnership Fund (IPF). IPF contributors are South Carolina businesses and individuals who receive a dollar-for-dollar state tax credit for investing in the state’s innovation economy.

  • sam patrick posted an article
    Helping patients stay out of hospital, recover faster see more

    Courtesy Columbia Regional Business Report

     

    Prisma Health is taking key elements of inpatient care into patients’ homes to help them stay out of the hospital under a new program for the Midlands called Home Recovery Care. 

    The model has been used at Prisma Health hospitals in the Upstate, according to a news release.  

    For patients under care through Prisma Health Richland Hospital, the organization partners with Nashville, Tenn.-based Contessa to deliver the service at its third site, the news release said. 

    The program launched at Greenville Memorial Hospital in 2019 and expanded to Oconee Memorial Hospital last year. In the Upstate, the program has a 90% acceptance rate and an average patient satisfaction score of 98%, according to the release.  

    Prisma Health was one of the first health systems approved to provide Home Recovery Care to Medicare fee-for-service patients under the Center for Medicare and Medicaid Services’ Hospitals Without Walls waiver, the release said. Programs that encourage hospitals to find healthy ways to stay out of emergency rooms and hospital rooms have been part of Medicare/Medicaid rules for years, with the COVID-19 pandemic spurring more efforts.  

    “Prisma Health has had great success with the program in the Upstate, and we are thrilled to provide this level of home care to more South Carolinians by adding it at Richland,” Bo Cofield, Prisma Health Richland Hospital CEO, said in the release. “The COVID-19 pandemic reinforced that going beyond the walls of the traditional hospital setting often gives our patients a better option for acute-level health care. Home Recovery Care was in place before the pandemic, but it is now gaining momentum. We believe this kind of service is essential to the care of our patients and is an important component of health care.” 

    Home recovery is more satisfying for patients and costs less than traditional recovery in a hospital, according to the release. 

    The care is for patients with acute, non-life-threatening medical conditions. Roughly 150 diagnoses are considered eligible for the service and range from congestive heart failure and pneumonia to dehydration, cellulitis and urinary tract infections. Patients must be evaluated by a Prisma Health doctor to determine if their conditions can be safely treated in the home instead of a standard hospital environment, according to the release. 

    The program includes 24-hour access to a recovery care coordinator and continual monitoring for up to 30 days, the release said. The in-home work is done by Prisma Health’s home-health registered nurses and by physician consultation utilizing telehealth. 

    “Since we launched the program, we have served 300 patients and saved patients from being hospitalized for 1,000 additional inpatient days,” Angela Orsky, vice president of post-acute services at Prisma Health, said in the release. “Our patient likelihood to recommend scores are 100, and we are exceeding all our quality targets. Our home health clinicians in partnership with our hospitalists have exceled in the ability to care for complex patients safely in their homes.”

  • sam patrick posted an article
    PMLS donates rapid antigen tests to Diabetes Education camps see more

    Premier Medical Laboratory Services donates rapid antigen tests to Diabetes Education and Camping Association Camps

    Many children with diabetes look forward to summer camp each year to, not only spend time with friends, but with other children who can relate to similar day-to-day obstacles that living with diabetes can present. The Diabetes Education and Camping Association (DECA) unites the global diabetes camping community, providing leadership, education, and resources to make camps for those with diabetes more impactful. As most summer camps across the US resumed this year, diabetes camps were faced with the extraordinary obstacle of protecting children who are at higher risk for COVID-19 complications due to diabetes. To bring summer camps for children living with diabetes back this year and to help protect these children, one of the nation’s largest laboratories, Premier Medical Laboratory Services, donated thousands of COVID-19 tests to DECA camps in 19 states across the nation, enabling them to safely return to camp this year.

    “We know DECA and each of their camps do so much for the diabetes community - helping kids to learn how to manage the disease as well as support emotional wellbeing,” said Kevin Murdock, Founder and CEO of PMLS. “With diabetes being a global pandemic, it’s a large focus for Premier Medical Laboratory Services to provide top healthcare solutions for patients with diabetes. We are honored to help camps that improve the lives of children and adolescents with diabetes.”

    For some children, a diabetes camp is their first opportunity to meet a friend who also has diabetes, or their first time staying somewhere without their parents. It’s a great place for them to adopt a new hobby or learn skills that give them more self-confidence. Along with the feeling of independence and support, diabetes camps have been shown to provide children with an increase in diabetes self-care abilities and decreased diabetes-specific distress. (1) For caregivers, diabetes camps provide a medically sound environment where they can feel assured that their children are safe and their diabetes care needs are met.

    Terry Ackley, Executive Director of DECA added: “The safety of children with diabetes is the highest priority of diabetes camps. Covid-19 has presented significant challenges to the operation of diabetes camps this year. It has required that they carefully study their program delivery model and incorporate additional health and safety protocols following the newest guidelines from the Centers for Disease Control. A tool that is very important to safely serving children with diabetes at camp is Covid-19 testing. Premier Medical Laboratory Services approached the diabetes camping community to offer their much-needed support. Our community greatly appreciates their generous donation of a large quantity of rapid antigen tests to diabetes camps across the United States. Premier Medical Laboratory Services has been instrumental to the ability of diabetes camps to operate this year. Their support is helping children learn more about how to manage their diabetes, build resilience to living with this difficult health condition, develop cherished friendships and have lots of fun!”

    Aside from offering COVID-19 testing and many other medical diagnostics solutions, PMLS is continually searching for innovative diabetes prevention and maintenance applications. With some of the most advanced testing panels for both type 1 and type 2 diabetes, PMLS also introduced to the US a first of its kind predictive genetic test for type 2 diabetes, which allows patients to know their risk of future onset of the disease determined by their individual genetic make-up. Along with this, Premier Medical Laboratory Services is currently working with the   Juvenile Diabetes Research Foundation on initiatives to bring soccer clinics to diabetes communities as part of their mission to improve patient lives both medically and through community outreach. PMLS is soon to announce more breakthrough solutions for diabetes care.

    For more information on Premier Medical Laboratory Services, please visit www.premedinc.com or call 866-387-2909.

  • sam patrick posted an article
    South Carolina-based firm names new head of pharma and medtech see more

    DUNCAN, SC - Stäubli announced today that Olivier Cremoux has been appointed Deputy Head of Pharma and Medical Device for Stäubli Robotics North America.

    Cremoux joined Stäubli Group in 2015 before transferring to Stäubli Corporation as the North American Business Development Manager for Robotics in 2018. Most recently, he became Key Account Manager – Pharma and will maintain this role throughout the transition period.  Cremoux will use his experience to help build the Medical Robotics team while focusing on the Pharma and Medical Device specific markets.

    Cremoux graduated from the National Institute of Science Applied of Lyon (France) with a bachelor degree in Electrical Engineering.

    Commenting on the announcement, North American Robotics Division Manager, Sebastien Schmitt stated, “We are pleased to announce Mr. Cremoux as Stäubli Robotics North American Deputy Head of Pharma and Medical Device. We believe Mr. Cremoux is the right leader for Pharma and Medical Device as we continue to expand our growing team.  This is an important step in setting up an organization fully dedicated to the pharmaceutical industry to build on our existing expertise in a number of high‑tech markets.”

    Olivier Cremoux: “I am honored by such an opportunity within Stäubli Robotics.  The Pharma and Medical Device is a strategic and growing market in which Stäubli has provided, for over 20 years, significant technological innovations.  High throughput screening, aseptic fill/finish, orthopedic surgery, bio-printing and cell culturing are examples of processes where Stäubli Robotics started as a pioneer and became a reference. With COVID-19 pandemic, robotics became even more essential to our customers, from drug production to Covid test manufacturing.  In North America, we will continue the development of our organization to ensure all current and future needs of our customers.”

    About Stäubli Robotics

    Stäubli Robotics is a leading global player in robotics, consistently delivering engineering as effective and reliable as our service and support. A complete solutions provider for digitally networked production, Stäubli offers a broad range of 4- and 6-axis robots including robotic arms designed specifically for sensitive environments, autonomous mobile robots, driver-less transport systems (AGVs) and cobots for human-robot collaboration.  www.Stäubli.com/robotics 

    About Stäubli North America

    Stäubli North America has more than 200 employees supporting Connectors, Robotics and Textiles customers. The company’s North American headquarters is in Duncan, South Carolina. Stäubli provides customer support through its locations in Duncan, Queretaro, Mexico, and the newest Stäubli North American facility, which opened in 2018 in Novi, Michigan. In addition to 24/7 customer support, each of these facilities offers training and has dedicated on-site technical experts who can be deployed whenever needed. Stäubli’s North American sales force is located strategically on the West and East coasts, and also serves Canada and Puerto Rico.

    Worldwide, Stäubli is a leading manufacturer of quick release couplings, robotics systems and textile machinery. With a workforce of more than 5,500 employees, Stäubli is present in 29 countries supported by a comprehensive distribution network in 50 countries worldwide.

  • sam patrick posted an article
    Lou Kennedy and Nephron Team step up for SC again see more

    Glove Plant Will Shore Up Domestic Supply Chain, Reduce American Dependence on Foreign Sources of Medical-Grade Gloves & Create New Jobs

    WEST COLUMBIA, S.C. – During a celebration attended by strategic partners, business leaders and public officials, Nephron Pharmaceuticals Corporation CEO Lou Kennedy and Governor Henry McMaster today announced the opening of Nephron Nitrile, a plant that will produce American-made, medical-grade nitrile gloves.

    The announcement is the latest Nephron expansion on the sprawling company campus located at Saxe-Gotha Industrial Park in Lexington County.

    Nephron Nitrile – which will be headquartered in more than 400,000 square feet of space in the Kennedy Innovation Complex – represents an investment of more than $100 million in the Midlands. The plant will generate 250 jobs for the area.

    “This is a historic day for our company, and, we believe, for South Carolina,” said Kennedy. “Over the course of the last year, we have poured every bit of creativity, energy and resources we have at our disposal into doing our part, as a proud Made-in-America manufacturer, to respond to an unprecedented crisis. Nephron Nitrile is the latest part of our ongoing effort to make South Carolina the nationwide example for effectively responding to America’s needs, this time by shoring up the domestic supply chain.”

    Kennedy and the governor, along with the entire Nephron team, have made reducing the American dependence on foreign sources of critical health care-related items, such as personal protective equipment (PPE) and lifesaving medications, a top priority. Kennedy joined the governor in April when he announced an executive order to safeguard South Carolina from supply chain disruptions, such as those caused by countries like China, experienced during the COVID-19 pandemic by working to manufacture even more essential, life-saving products in South Carolina.

    Now, just months later, Kennedy and her team at Nephron are stepping up once again. In doing the work on the front end of the announcement to secure partnerships with trusted companies to provide raw materials, machinery and technology, Nephron is in position to make a significant difference in bolstering the PPE supply chain by early 2022.

    “It is critical that South Carolina lead the charge in bringing the production of life-saving medications and supplies back home to the United States,” said Governor McMaster. “After last year’s supply chain disruptions caused by the COVID-19 pandemic, I announced a new initiative aimed at expanding recruitment efforts of pharmaceutical and medical supply manufacturers in the Palmetto State. Nephron Pharmaceuticals Corporation’s continued investment in South Carolina and our people will go a long way toward creating much-needed independence in this industry. This great company continues to show that we have the talent and the ability to do anything we put our minds to, right here in South Carolina.”

    Last July, Kennedy announced an investment of $215 million for Lexington County, bringing 380 new full-time jobs to the area by 2024, and adding new office, warehouse and vaccine production space. This announcement included the establishment of the Kennedy Innovation Complex, home of Nephron Nitrile, and these projects are ahead of schedule. Since re-locating company headquarters to Lexington County from Orlando, Nephron has invested more than a half billion dollars in the region, creating almost 2,000 full and part time jobs.

    “Lexington County is beyond excited to say congratulations again to Nephron Pharmaceuticals,” said Lexington County Council Chairman M. Todd Cullum. “The county is enthusiastic about this announcement as much or more than the company’s original announcement to locate in Lexington County. Their investment in hard assets and jobs is second to none in South Carolina. Nephron’s partnership with Lexington County has been tremendous in helping to improve the quality of life in our county and the region. We can’t wait to see what the future holds for this extraordinary company.”

    A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. Nephron launched a CLIA-certified diagnostics lab last year where it tests people for COVID-19 and administers vaccinations.

    For more information regarding Nephron Nitrile, including orders and partnerships, please email: NephronNitrile@nephronpharm.com.